CLinical Evaluation of Aspiration for Removal ANd ClearancE of Stones

NCT06615713 — Not applicable, Completed, 30 participants, Calyxo, Inc.

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Prospective Study to Evaluate the Safety and Effectiveness of Steerable Ureteroscopic Renal Evacuation (SURE) Using the CVAC® Set

RegistryNCT06615713, acronym CLEARANCE
StatusCompleted
PhaseNot applicable
Study typeInterventional; na, single group, masking: none, treatment
Enrollment30 (Actual)
SponsorCalyxo, Inc. (Industry)
ConditionsRenal Stones, Kidney Stone, Urolithiasis
InterventionsSteerable Ureteroscopic Renal Evacuation (SURE) with the CVAC System (Device)
Datesstart 2024-09-05, primary completion 2025-01-31, completion 2025-01-31, first posted 2024-09-27, last updated 2026-04-28
Locations1 site in India

Related Papers Related Patents Related Grants Related Experts
All trials for Renal Stones All trials for Kidney Stone All trials of Steerable Ureteroscopic Renal Evacuation (SURE) with the CVAC System

-Summary

The purpose of the study is to assess safety and efficacy of a novel steerable ureteral catheter system, the CVAC System for the treatment of urinary stones.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Steerable Ureteroscopic Renal Evacuation (SURE) with the CVAC SystemExperimentalDevice: Steerable Ureteroscopic Renal Evacuation (SURE) with the CVAC SystemThe CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).
  • Steerable Ureteroscopic Renal Evacuation (SURE) with the CVAC System (Device): The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).

+Outcome measures

Primary outcomes

  • Stone Clearance (% Reduction in Stone Volume) [30 Days]: The percent reduction (\[Baseline stone volume- 30-Day stone volume\] / Baseline stone volume) in stone volume following intervention, observed on non-contrast CT (NCCT) (2.0mm slice thickness). A positive result indicates a decrease in stone volume removed during the procedure; a negative value indicates an increase in stone volume following the procedure.
  • Residual Stone Volume (RSV) [30 Days]: A continuous quantitative measure of remaining stone volume following intervention, observed on non-contrast CT (NCCT) (2.0mm slice thickness).
  • Stone Free Rate (SFR) - Zero Fragments [30 Days]: Where stone free status is defined as zero residual fragments at 30 days observed on non-contrast CT (NCCT) (2.0mm slice thickness). SFR is calculated by determining the number of kidneys in each treatment arm with a stone free status of zero fragments and dividing that by the total number of kidneys treated in the respective treatment arm.

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Candidate for ureteroscopy with laser lithotripsy;
* Be willing and able to return for and respond to all study-related follow up procedures; and,
* Have been informed of the nature of the study and have agreed to the IRB approved informed consent form (ICF).

Exclusion Criteria:

* Significant morbidities;
* Unable to meet the treatment and follow up protocol requirements; and,
* Ureteral or kidney abnormalities.

+Posted results

Participant flow

MilestoneSteerable Ureteroscopic Renal Evacuation (SURE) With the CVAC System
Started30
Completed26
Not completed4

Outcome results

  • Stone Clearance (% Reduction in Stone Volume) (Primary), Mean, % stone volume removed: Steerable Ureteroscopic Renal Evacuation (SURE) With the CVAC System 96.2 +/- 6.5
  • Residual Stone Volume (RSV) (Primary), Mean, mm^3: Steerable Ureteroscopic Renal Evacuation (SURE) With the CVAC System 14.1 +/- 23.0
  • Stone Free Rate (SFR) - Zero Fragments (Primary), Count of units, kidneys: Steerable Ureteroscopic Renal Evacuation (SURE) With the CVAC System 13

Adverse events

Time frame: Index Procedure to Post-op Day-30 (POD30)

ArmDeathsSerious adverse eventsOther adverse events
Steerable Ureteroscopic Renal Evacuation (SURE) With the CVAC System0/30 (0.0%)0/30 (0.0%)2/30 (6.7%)

Other adverse events by term

TermOrgan systemSteerable Ureteroscopic Renal Evacuation (SURE) With the CVAC System
Urinary Tract Infection (UTI)Renal and urinary disorders2/30

+Locations (1)

FacilityCityCountryStatus
Muljibhai Patel Urological HospitalNadiādIndia

+Study documents